Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMANA
NCT00788177Phase 3Unknown
- Sponsor
- Klinikum Ludwigshafen
- Start
- Nov 2008
- Primary completion
- Mar 2012
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 3 trial of pegaptanib sodium in neovascular age-related macular degeneration (NVAMD), sponsored by Klinikum Ludwigshafen. Status: unknown.
02
Drugs
pegaptanib sodium
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00788177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00788177.